Hier
exithub.com/...-acquire-biodel-biod-in-stock-for-stock-merger/
findet sich die Antwort, warum Albireo Biodel braucht. Sie wollen vor allem deren Geld:
Albireo CEO Cooper:
“This transaction with Biodel and concurrent financing is expected to provide Albireo with sufficient capital to advance our lead product candidate, A4250, through an important Phase 2 clinical readout later this year and a subsequent planned pivotal trial in PFIC"
Dazu Biodel-CEO Gemignani:
"We are optimistic that the promise of Albireo’s pipeline and the strength of its leadership team, coupled with Biodel’s cash resources, will enable the combined company to reach significant milestones.”
Weitere Info:
"Albireo Ltd, a privately held Swedish biopharmaceutical company, agreed to acquire Biodel Inc. (NASDAQ: BIOD) in a stock-for-stock merger deal. At closing Biodel will change its name to Albireo Pharma Inc. and its ticker symbol on the NASDAQ Capital Market will be ranamed ALBO. The combined company will focus on the development of novel bile acid modulators to treat orphan pediatric liver diseases, as well as other liver and gastrointestinal diseases and disorders....
The proposed transaction has been approved by the boards of directors of both companies and by the Albireo stockholders. It is expected to close in the third calendar quarter of 2016, subject to the approval of the Biodel stockholders and other customary conditions."
Jetzt meine persönliche Meinung dazu: ich kann an der Merger-Bekanntgabe nichts Negatives finden. Und schon gar nichts, was die derzeit niedrigeren Kurse als vor der Bekanntgabe rechtfertigen würde.
Ich würde auch die SD-Prognose unterschreiben, dass mit der Durchführung des Mergers im dritten Quartal der Kurs höher steigen wird als die 70 Eurocent von vor ein paar Tagen.
Sieht das jemand anders? Und wenn ja, warum?
Zurück
Weiter
